ENAGenomicsSylvain Guérin, CUO-Recherchehttps://www.ebi.ac.uk/ena/browser/view/PRJNA850000Homo sapiensxref:PubMed:36139479The objective of this study was to find deregulated genes between healthy and psoriatic T cell-enriched tissue-engineered models to develop a new therapeutic pathway in psoriasis treatment. In this study, we used a tissue-engineered, two-layers (dermis and epidermis) human skin substitute enriched in T cells as a biomaterial to study both the cellular and molecular mechanisms involved in psoriasis’ pathogenesis. Overall design: 3 human healthy keratinocytes population (at passage 3) from 3 healthy donors (18-, 46- and 49-years old), 4 human psoriatic keratinocytes population (at passage 3) from directly into the lesion of 4 psoriatic patients (36-, 46-, 49- and 64- years old) and 3 human psoriatic keratinocytes population (at passage 3) from area without lesion of three psoriatic patients (46-, 49- and 64- years old) co-cultured or not with T-lymphocyte from human tissue-engineered skin substitutes are analyzed by gene profiling.ENAfalseGene expression in human keratinocytes from psoriatic skin (directly into the lesion or in area without lesion) or healthy person (control) used for human tissue-engineered skin substitutes and co-cultured with T-lymphocyteGene expression in human keratinocytes from psoriatic skin (directly into the lesion or in area without lesion) or healthy person (control) used for human tissue-engineered skin substitutes and co-cultured with T-lymphocyte2025-09-242022-06-19PRJNA850000GSE206311960636139479